A Neutrophil Elastase Inhibitor, Sivelestat, Reduces Lung Injury Following Endotoxin-Induced Shock in Rats by Inhibiting HMGB1

[1]  J. Mccollam,et al.  Recognizing and Managing Severe Sepsis: A Common and Deadly Threat , 2007, Southern medical journal.

[2]  I. Fukuda,et al.  Neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury after cardiopulmonary bypass in the rabbit endotoxemia model. , 2007, The Annals of thoracic surgery.

[3]  D. Pisetsky,et al.  The role of IFN-alpha and nitric oxide in the release of HMGB1 by RAW 264.7 cells stimulated with polyinosinic-polycytidylic acid or lipopolysaccharide. , 2006, Journal of immunology.

[4]  K. Tracey,et al.  HMGB1 SIGNALS THROUGH TOLL-LIKE RECEPTOR (TLR) 4 AND TLR2 , 2006, Shock.

[5]  A. Norrby-Teglund,et al.  The role of high mobility group box-1 protein in severe sepsis , 2006, Current opinion in infectious diseases.

[6]  I. A. Schettino,et al.  The lung in sepsis: guilty or innocent? , 2006, Endocrine, metabolic & immune disorders drug targets.

[7]  E. Lillehoj,et al.  Neutrophil elastase induces IL-8 gene transcription and protein release through p38/NF-{kappa}B activation via EGFR transactivation in a lung epithelial cell line. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[8]  A. Malik,et al.  NF-κB activation as a pathological mechanism of septic shock and inflammation , 2006 .

[9]  E. Abraham,et al.  High mobility group box 1 protein interacts with multiple Toll-like receptors. , 2006, American journal of physiology. Cell physiology.

[10]  L. Traber,et al.  Sepsis: emerging role of nitric oxide and selectins. , 2006, Clinics.

[11]  A. Malik,et al.  NF-kappa B activation as a pathological mechanism of septic shock and inflammation. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[12]  M. Antonelli,et al.  Year in review in intensive care medicine, 2005. II. Infection and sepsis, ventilator-associated pneumonia, ethics, haematology and haemostasis, ICU organisation and scoring, brain injury , 2006, Intensive Care Medicine.

[13]  Y. Abe,et al.  Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation , 2005, Thrombosis and Haemostasis.

[14]  K. Tracey,et al.  Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock* , 2005, Critical care medicine.

[15]  M. Antonelli,et al.  Year in review in intensive care medicine, 2004. I. Respiratory failure, infection, and sepsis , 2004, Intensive Care Medicine.

[16]  Masaki Tanaka,et al.  Contributions of high mobility group box protein in experimental and clinical acute lung injury. , 2004, American journal of respiratory and critical care medicine.

[17]  R. Bellomo,et al.  Hidden evidence to the West: multicentre, randomised, controlled trials in sepsis and systemic inflammatory response syndrome in Japanese journals , 2004, Intensive Care Medicine.

[18]  S. Moochhala,et al.  Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome , 2004, The Journal of pathology.

[19]  G. Downey,et al.  Proteases and lung injury , 2003, Critical care medicine.

[20]  D. Herndon,et al.  Heparin Nebulization Attenuates Acute Lung Injury in Sepsis Following Smoke Inhalation in Sheep , 2002, Shock.

[21]  K. Tracey,et al.  HMGB1 as a late mediator of lethal systemic inflammation. , 2001, American journal of respiratory and critical care medicine.

[22]  T. Pritts,et al.  Activation of NF-kappaB varies in different regions of the gastrointestinal tract during endotoxemia. , 2000, Shock.

[23]  K. Tracey,et al.  Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. , 1999, Surgery.

[24]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[25]  S. Akira,et al.  Unresponsiveness of MyD88-deficient mice to endotoxin. , 1999, Immunity.

[26]  P. Ricciardi-Castagnoli,et al.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. , 1998, Science.

[27]  Adcock Im.  Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. , 1997 .

[28]  I. Adcock.  Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. , 1997, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[29]  Vender Rl.  Therapeutic potential of neutrophil-elastase inhibition in pulmonary disease. , 1996 .

[30]  R. Shenkar,et al.  Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. , 1996, Critical care medicine.

[31]  A. Ishizaka,et al.  Effect of a specific neutrophil elastase inhibitor, ONO-5046, on endotoxin-induced acute lung injury. , 1996, American journal of respiratory and critical care medicine.

[32]  R. Vender.  Therapeutic potential of neutrophil-elastase inhibition in pulmonary disease. , 1996, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[33]  M. Suzuki,et al.  ONO-5046, a novel inhibitor of human neutrophil elastase. , 1991, Biochemical and biophysical research communications.

[34]  S. Weiss.  Tissue destruction by neutrophils. , 1989, The New England journal of medicine.

[35]  S. Crawford.  NEUTROPHILS AND ADULT RESPIRATORY DISTRESS SYNDROME , 1984, The Lancet.